Casdin Capital 13F holdings, Q2 2016
Holdings as of June 30, 2016 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 24 US equity positions worth $95.7m in its Q2 2016 13F filing. The largest position was SPARK THERAPEUTICS INC at 8.7% of the reported book, followed by AGIO and FOUNDATION MEDICINE INC. Against the Q1 2016 filing, it opened 6 new positions, added to 8 and reduced 9 among the top 24 holdings.
What did Casdin Capital own in Q2 2016? Top 24 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2016 |
|---|---|---|---|---|---|---|---|
| 1 | SPARK THERAPEUTICS INC | 8.7% | $8.3m | 162,500 | -4% | reduced | |
| 2 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 8.2% | $7.9m | 187,500 | 27% | added |
| 3 | FOUNDATION MEDICINE INC | 7.6% | $7.3m | 390,000 | 16% | added | |
| 4 | GLOBAL BLOOD THERAPEUTICS IN | 7.5% | $7.1m | 430,000 | 310% | added | |
| 5 | LOXO ONCOLOGY INC | 7.3% | $7.0m | 300,000 | 20% | added | |
| 6 | 2655787D BLUEPRINT MEDICINES CORP | 7.2% | $6.9m | 340,000 | 6% | added | |
| 7 | SG7 SAGE THERAPEUTICS INC | 7.2% | $6.9m | 228,500 | 21% | added | |
| 8 | BLUEBIRD BIO INC | 5.5% | $5.3m | 122,500 | 2% | added | |
| 9 | EVH EVOLENT HEALTH INC | Healthcare | 4.8% | $4.6m | 239,500 | – | new |
| 10 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 4.2% | $4.0m | 72,500 | -19% | reduced |
| 11 | KITE PHARMA INC | 3.8% | $3.6m | 72,500 | -3% | reduced | |
| 12 | GNMK GENMARK DIAGNOSTICS INC | 3.8% | $3.6m | 415,000 | – | new | |
| 13 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 3.7% | $3.5m | 322,500 | -5% | reduced |
| 14 | EPIZYME INC | 3.6% | $3.5m | 340,000 | -38% | reduced | |
| 15 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 2.5% | $2.4m | 234,179 | -27% | reduced |
| 16 | MYOKARDIA INC | 2.3% | $2.2m | 179,029 | -62% | reduced | |
| 17 | CLOVIS ONCOLOGY INC | 2.2% | $2.1m | 150,000 | – | new | |
| 18 | IGNYTA INC | 2.1% | $2.0m | 375,000 | 241% | added | |
| 19 | AVEXIS INC | 1.8% | $1.7m | 45,000 | -29% | reduced | |
| 20 | T8S TESARO INC | 1.8% | $1.7m | 20,000 | – | new | |
| 21 | BMY BRISTOL MYERS SQUIBB CO | Healthcare | 1.6% | $1.5m | 21,000 | 0% | held |
| 22 | DXCM DEXCOM INC | Healthcare | 1.2% | $1.2m | 15,000 | -62% | reduced |
| 23 | SYROS PHARMACEUTICALS INC | 0.9% | $908.0k | 50,000 | – | new | |
| 24 | MEDGENICS INC | 0.5% | $472.0k | 85,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.